PMID- 15137060 OWN - NLM STAT- MEDLINE DCOM- 20040702 LR - 20211203 IS - 0021-9541 (Print) IS - 0021-9541 (Linking) VI - 200 IP - 1 DP - 2004 Jul TI - HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA. PG - 82-8 AB - The increased levels of c-Myc protein observed previously in an ovarian carcinoma cell line stably transfected to express HER2 has suggested a role for the HER2 pathway in c-Myc expression. Analysis of HER2-transfected cells stimulated with heregulin beta1 (HRG) revealed increased c-Myc protein levels but not a corresponding increase in c-Myc mRNA expression or any change in c-Myc protein half-life. Transfection of HER2-overexpressing cells with a construct containing the 5' untranslated region (5'UTR) of c-Myc mRNA originated from the P2 promoter and placed upstream of the Renilla luciferase gene, enhanced reporter expression upon stimulation with HRG. The HRG-mediated increase in reporter activity correlated with the HRG-mediated induction observed for c-Myc protein, identifying the P2-derived leader (P2L) of c-Myc mRNA as the cis-element involved in c-Myc translational induction. Both the increase in c-Myc protein levels and P2L-enhanced translational activity were inhibited by the PI3K inhibitor wortmannin. Together, these results demonstrate that HRG stimulation of HER2 overexpressing cells leads to enhanced c-Myc protein synthesis through activation of the PI3K/Akt/mTOR pathway and that the P2L of c-Myc mRNA is the element responsible for induction of c-Myc translation. CI - Copyright 2004 Wiley-Liss, Inc. FAU - Galmozzi, Enrico AU - Galmozzi E AD - Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy. FAU - Casalini, Patrizia AU - Casalini P FAU - Iorio, Marilena Valeria AU - Iorio MV FAU - Casati, Barbara AU - Casati B FAU - Olgiati, Clelia AU - Olgiati C FAU - Menard, Sylvie AU - Menard S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (5' Untranslated Regions) RN - 0 (Androstadienes) RN - 0 (Enzyme Inhibitors) RN - 0 (Neuregulin-1) RN - 0 (Protein Synthesis Inhibitors) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Proto-Oncogene Proteins c-myc) RN - 0 (RNA, Messenger) RN - 155646-83-6 (heregulin beta1) RN - 1CC1JFE158 (Dactinomycin) RN - 98600C0908 (Cycloheximide) RN - EC 1.13.12.- (Luciferases) RN - EC 2.7.- (Protein Kinases) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (AKT1 protein, human) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - XVA4O219QW (Wortmannin) SB - IM ECI - J Cell Physiol. 2021 Sep;236(9):6772. PMID: 34160080 MH - 5' Untranslated Regions/*metabolism MH - Androstadienes/pharmacology MH - Carcinoma/genetics/metabolism/pathology MH - Cell Line, Tumor MH - Clone Cells MH - Cycloheximide/pharmacology MH - Dactinomycin/pharmacology MH - Enzyme Inhibitors/pharmacology MH - Female MH - Gene Expression Regulation, Neoplastic/drug effects MH - Genes, Reporter MH - Genes, erbB-2 MH - Genes, myc/*drug effects MH - Humans MH - Luciferases/metabolism MH - Neuregulin-1/*metabolism/pharmacology MH - Ovarian Neoplasms/genetics/metabolism/pathology MH - Phosphatidylinositol 3-Kinases/metabolism MH - Promoter Regions, Genetic MH - *Protein Biosynthesis/drug effects MH - Protein Kinases/metabolism MH - *Protein Serine-Threonine Kinases MH - Protein Synthesis Inhibitors/pharmacology MH - Proto-Oncogene Proteins/metabolism MH - Proto-Oncogene Proteins c-akt MH - Proto-Oncogene Proteins c-myc/*biosynthesis/genetics MH - RNA, Messenger/*genetics/metabolism MH - Signal Transduction MH - TOR Serine-Threonine Kinases MH - Wortmannin EDAT- 2004/05/12 05:00 MHDA- 2004/07/03 05:00 CRDT- 2004/05/12 05:00 PHST- 2004/05/12 05:00 [pubmed] PHST- 2004/07/03 05:00 [medline] PHST- 2004/05/12 05:00 [entrez] AID - 10.1002/jcp.20012 [doi] PST - ppublish SO - J Cell Physiol. 2004 Jul;200(1):82-8. doi: 10.1002/jcp.20012.